CDT Equity Inc. validates enhanced properties for drug compounds

CDT Equity Inc. has announced that new solid forms and alternative crystal structures of its existing drug compounds demonstrate enhanced physical properties. These improvements include better stability, solubility, and manufacturability compared to previous versions.

These findings are protected under the company’s Substance of Matter intellectual property. CDT utilized Sarborg’s Signature Intelligence to identify these new potential uses, which target diseases with limited treatment options and underserved patient groups. The company plans to advance these findings into clinical lab models to build experimental evidence of therapeutic potential before entering partnering discussions.